Breakthrough Technologies in Medicine: Evolution, Revolution, Organization

24 May , 15:00–16:15
Technology for Leadership
Panel Session
Congress Centre, Conference Hall D3

Breakthrough innovative technologies offer solutions that are simpler, more convenient, and cheaper. They disrupt the market and displace older players. Today, there are two key trends in healthcare: the first is the evolution of existing and very expensive technologies, often requiring highly qualified specialists to implement them. The second is a revolution of breakthrough innovations based on new physical principles and solutions. For example, simpler reconstructive heart vessel surgery can replace a dangerous and prolonged bypass operation. The use of portable devices for self-monitoring of blood sugar reduces the need for visits to the endocrinologist, while digital technology will give patients the opportunity to manage their health. Creating a balance between expensive and breakthrough technologies allows for the accelerated development of the industry, and this task is the responsibility of the organizers of the public health system. What breakthrough technologies are already having an impact on healthcare today? What breakthrough healthcare technologies will businesses be able to offer tomorrow? What system should the state use to support scientific research? What are the barriers to the introduction of breakthrough technologies, and how can they be overcome? How will artificial intelligence change the roles of the doctor, nurse, and patient? How can an effective relationship between business, regulators, and consumers be established?

Guzel Ulumbekova, President of the Board, Association of Medical Societies for Quality of Medical Care and Medical Education; Head, Higher School of Healthcare Organization and Management

Kostas Varlas, Regional European Director, Diagnostics Division (ADD), Abbott Laboratories
Zeger Vercouteren, Vice President for Government Affairs and Policy, Europe, Middle East and Africa (EMEA), Johnson & Johnson
Anthony Wong, Regional Vice President, Russia, Ukraine and CIS, AbbVie
Trevor Gunn, Vice President for International Relations, Medtronic
Petr Glybochko, Rector, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Alexander Ivlev, Country Managing Partner for Russia, EY
Dmitry Morozov, General Director, BIOCAD
Veronika Skvortsova, Minister of Healthcare of the Russian Federation
Arkadiy Stolpner, Chairman of the Board of Directors, DTC IIBS
Sergey Tsyb, Deputy Minister of Industry and Trade of the Russian Federation
Evgeniy Shlyakhto, Director General, Almazov National Medical Research Centre; President, All-Russian Non-Governmental Organization "Russian Society of Cardiology"

Front row participants
Michael Ball, Chief Executive Officer, Alcon
Elena Brusilova, President, International Clinic MEDSI
Matthias Wernicke, General Manager, Merck Biopharma Russia and CIS
Michael McGannon, Co-Founder, McGannon Institute of Proactive Health
Eyal Mishani, Head, Cyclotron Radiochemistry Unit, Hadassah Hebrew University Hospital
Mikhail Murashko, Head, Federal Service on Surveillance in Healthcare
Irina Panarina, General Manager, Russia and Eurasia, AstraZeneca